Cyient DLM (CYIENTDLM)

FairStock Score: 40/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Conservative balance sheet with debt/equity of 0.17 reduces financial risk.
• Promoter holding of 52.12% aligns interests with minority shareholders.
• Piotroski F-Score of 6/9 suggests no immediate financial distress.
• ROCE of 10.99% on a low-debt balance sheet is not a value destroyer.
• Profit grew 2.18% despite 31.71% sales decline, showing some earnings resilience.

Concerns

• Sales growth of -31.71% indicates a severe top-line contraction.
• P/E of 30.30 and P/B of 3.21 look expensive against ROE of 7.21%.
• PEG of 13.90 suggests the valuation is far above underlying growth.
• Zero dividend yield means no income while waiting for uncertain capital gains.

AI Analysis

Let me start with what I value: a business I understand, a strong balance sheet, and a price that leaves room for error. Cyient DLM operates in industrial products. The first thing I see is a sharp revenue decline. Sales growth is minus 31.71%. Profit growth of 2.18% is positive, but with sales falling that hard, I have to question earnings quality. The latest quarter shows sales of ₹303 crore and net profit of ₹11 crore, a thin margin of about 3.6%. The market capitalizes this company at ₹2,481 crore and asks me to pay a P/E of 30.30 and a P/B of 3.21. For a business earning an ROE of only 7.21%, paying more than three times book value is not a bargain. At ₹381.50, against book value of ₹118.89, I need either much higher future returns or a speculative multiple expansion. Graham would say the margin of safety is missing. The balance sheet is the one bright spot: debt/equity of 0.17 is conservative, and the Piotroski F-score of 6/9 suggests no immediate distress. Promoter holding of 52.12% is a positive alignment. ROCE of 10.99% is reasonable but not exceptional. There is no dividend; I receive no income while waiting. The PEG of 13.90 confirms the price is far too rich for the company’s growth. The reported free cash flow of ₹213.57 lakh crore appears to be a data error; I cannot rely on it for valuation. With a risk score of 14/100, the signal is clearly cautious. This looks like a cyclical business, possibly in a downcycle. The stock has fallen from ₹737.55, but a falling price alone is not a reason to buy. I would wait for evidence of sustained sales recovery and a meaningful improvement in returns on capital before considering Cyient DLM.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer